12943623

Source:http://linkedlifedata.com/resource/pubmed/id/12943623

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013216, umls-concept:C0023981, umls-concept:C0032790, umls-concept:C0206034, umls-concept:C0546837, umls-concept:C0817096
pubmed:issue	7
pubmed:dateCreated	2003-8-28
pubmed:abstractText	Neither postoperative radiotherapy nor chemotherapy alone provided a survival benefit after curative esophagectomy for esophageal squamous carcinoma.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8504356
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin, http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Markers, Biological, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53
pubmed:status	MEDLINE
pubmed:month	Sep
pubmed:issn	0748-7983
pubmed:author	pubmed-author:FootA SAS, pubmed-author:FujiiTT, pubmed-author:KinugasaSS, pubmed-author:NagasueNN, pubmed-author:ShibakitaMM, pubmed-author:TachibanaMM, pubmed-author:UedaSS, pubmed-author:YoshimuraHH
pubmed:issnType	Print
pubmed:volume	29
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	580-7
pubmed:dateRevised	2009-11-3
pubmed:meshHeading	pubmed-meshheading:12943623-Aged, pubmed-meshheading:12943623-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:12943623-Chemotherapy, Adjuvant, pubmed-meshheading:12943623-Cisplatin, pubmed-meshheading:12943623-Drug Administration Schedule, pubmed-meshheading:12943623-Esophageal Neoplasms, pubmed-meshheading:12943623-Esophagectomy, pubmed-meshheading:12943623-Female, pubmed-meshheading:12943623-Fluorouracil, pubmed-meshheading:12943623-Gene Expression Regulation, Neoplastic, pubmed-meshheading:12943623-Humans, pubmed-meshheading:12943623-Immunohistochemistry, pubmed-meshheading:12943623-Lymphatic Metastasis, pubmed-meshheading:12943623-Male, pubmed-meshheading:12943623-Microcirculation, pubmed-meshheading:12943623-Middle Aged, pubmed-meshheading:12943623-Mutation, pubmed-meshheading:12943623-Neoplasm Invasiveness, pubmed-meshheading:12943623-Neoplasm Staging, pubmed-meshheading:12943623-Neovascularization, Pathologic, pubmed-meshheading:12943623-Postoperative Period, pubmed-meshheading:12943623-Predictive Value of Tests, pubmed-meshheading:12943623-Prospective Studies, pubmed-meshheading:12943623-Radiotherapy, Adjuvant, pubmed-meshheading:12943623-Radiotherapy Dosage, pubmed-meshheading:12943623-Survival Analysis, pubmed-meshheading:12943623-Thorax, pubmed-meshheading:12943623-Treatment Outcome, pubmed-meshheading:12943623-Tumor Markers, Biological, pubmed-meshheading:12943623-Tumor Suppressor Protein p53
pubmed:year	2003
pubmed:articleTitle	Postoperative chemotherapy vs chemoradiotherapy for thoracic esophageal cancer: a prospective randomized clinical trial.
pubmed:affiliation	Department of Digestive and General Surgery, Shimane Medical University, Enya-cho 89-1, Izumo 693-8501, Shimane, Japan. nigeka35@shimane-med.ac.jp
pubmed:publicationType	Journal Article, Clinical Trial, Randomized Controlled Trial